Oregon Health & Science University president stepping down

Joe Robertson, MD, the president of Oregon Health & Science University (OHSU) since 2006, has announced he’ll retire at the end of October after being diagnosed with multiple sclerosis earlier this year.

“My diagnosis was a shock to me and my family,” Robertson said in a statement. “While my doctors assure me that I could continue to execute my role as president, this news has compelled me to re-evaluate my future and my family’s well-being.”

His official retirement date of Oct. 31 doesn’t mean he’ll stop serving as president. The university’s press release said Robertson offered to stay in the role through the end of the academic year without a salary, as he can begin receiving his pension from the state of Oregon on Nov. 1. The OSHU board will consider his offer to serve through June 15, 2018 at its next board meeting.

Beyond that date, he said he wished to continue serving in a part-time faculty role at OSHU’s Casey Eye Institute.

“I recognize that my plans might not be everyone’s idea of retirement, but my OHSU colleagues will understand that medical practice isn’t just a job we do, it is part of who we are,” Robertson said.

Robertson first joined OHSU as an ophthalmology resident in 1979, then became a part of the faculty in 1985. Since taking over as president, the university has opened several new facilities, including its 412,000-square foot Center for Health & Healing and establishing a new school of public health in partnership with Portland State University. OSHU was ranked No. 4 in the country for primary care and No. 29 for research in the most recent U.S. News and World Report rankings for medical schools.

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.